JP2023544716A5 - - Google Patents

Info

Publication number
JP2023544716A5
JP2023544716A5 JP2023519608A JP2023519608A JP2023544716A5 JP 2023544716 A5 JP2023544716 A5 JP 2023544716A5 JP 2023519608 A JP2023519608 A JP 2023519608A JP 2023519608 A JP2023519608 A JP 2023519608A JP 2023544716 A5 JP2023544716 A5 JP 2023544716A5
Authority
JP
Japan
Prior art keywords
methylpyridine
pyrazole
acetamide
quinoline
benzoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023519608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544716A (ja
JP7752684B2 (ja
Filing date
Publication date
Priority claimed from EP20382861.1A external-priority patent/EP3978487A1/en
Application filed filed Critical
Publication of JP2023544716A publication Critical patent/JP2023544716A/ja
Publication of JP2023544716A5 publication Critical patent/JP2023544716A5/ja
Application granted granted Critical
Publication of JP7752684B2 publication Critical patent/JP7752684B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023519608A 2020-09-30 2021-09-29 トランスフォーミング増殖因子-β受容体I/ALK5の阻害剤としての2-(3-ピリジン-2-イル-4-キノリン-4-イル-ピラゾール-1-イル)-アセタミド誘導体 Active JP7752684B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382861.1A EP3978487A1 (en) 2020-09-30 2020-09-30 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
EP20382861.1 2020-09-30
PCT/EP2021/076730 WO2022069509A1 (en) 2020-09-30 2021-09-29 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Publications (3)

Publication Number Publication Date
JP2023544716A JP2023544716A (ja) 2023-10-25
JP2023544716A5 true JP2023544716A5 (cg-RX-API-DMAC7.html) 2024-10-08
JP7752684B2 JP7752684B2 (ja) 2025-10-10

Family

ID=72744716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519608A Active JP7752684B2 (ja) 2020-09-30 2021-09-29 トランスフォーミング増殖因子-β受容体I/ALK5の阻害剤としての2-(3-ピリジン-2-イル-4-キノリン-4-イル-ピラゾール-1-イル)-アセタミド誘導体

Country Status (20)

Country Link
US (1) US12577230B2 (cg-RX-API-DMAC7.html)
EP (3) EP3978487A1 (cg-RX-API-DMAC7.html)
JP (1) JP7752684B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230079027A (cg-RX-API-DMAC7.html)
CN (1) CN116323601B (cg-RX-API-DMAC7.html)
AR (1) AR123543A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021353965A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023004612A2 (cg-RX-API-DMAC7.html)
CA (1) CA3196108A1 (cg-RX-API-DMAC7.html)
DK (1) DK4222149T3 (cg-RX-API-DMAC7.html)
ES (1) ES3029607T3 (cg-RX-API-DMAC7.html)
FI (1) FI4222149T3 (cg-RX-API-DMAC7.html)
IL (1) IL301663B2 (cg-RX-API-DMAC7.html)
LT (1) LT4222149T (cg-RX-API-DMAC7.html)
MX (1) MX2023002900A (cg-RX-API-DMAC7.html)
PH (1) PH12023550777A1 (cg-RX-API-DMAC7.html)
PT (1) PT4222149T (cg-RX-API-DMAC7.html)
RS (1) RS68301B1 (cg-RX-API-DMAC7.html)
WO (1) WO2022069509A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202302393B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022010251A2 (pt) 2019-11-28 2022-09-06 Origo Biopharma S L Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta
WO2026017797A1 (en) 2024-07-17 2026-01-22 Agomab Spain S.L.U. Crystalline forms
WO2026082960A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv 1,5-naphtyridine and quinoline based inhibitors of alk5
WO2026082968A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv Novel compounds
CN121554469B (zh) * 2026-01-23 2026-04-17 四川大学华西医院 一种alk5 protac化合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501112A (en) * 1997-05-22 2002-10-25 G Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
ATE291020T1 (de) * 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
WO2004026306A2 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004026302A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
JP2009500419A (ja) * 2005-07-05 2009-01-08 アリックス セラピューティクス、インコーポレイテッド 立体異性体のピリジル及びピリドニル化合物並びに消化管障害及び中枢神経系障害の治療方法
CN102056907B (zh) * 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
RU2612958C2 (ru) * 2011-07-13 2017-03-14 Ск Кемикалз Ко., Лтд. 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
IN2014CN02805A (cg-RX-API-DMAC7.html) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
JP2021518855A (ja) 2018-03-02 2021-08-05 ユニヴェルシテ ド ローザンヌ Wntシグナル伝達経路阻害剤としてのピラゾール誘導体
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
CN110433164A (zh) 2019-08-15 2019-11-12 南开大学 TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用
BR112022010251A2 (pt) 2019-11-28 2022-09-06 Origo Biopharma S L Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta

Similar Documents

Publication Publication Date Title
CA3093851A1 (en) Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
RU2004117887A (ru) Ариланилиновые агонисты бета2 адренергических рецепторов
JP2017502033A5 (cg-RX-API-DMAC7.html)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2022505841A5 (cg-RX-API-DMAC7.html)
JP2005538099A5 (cg-RX-API-DMAC7.html)
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
JP2021535112A5 (cg-RX-API-DMAC7.html)
CN107325048A (zh) 使用c‑Met调节剂的方法
ES3029607T1 (en) 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
RU2005137403A (ru) Новые замещенные 3-сера-индолы
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
JP2008509187A5 (cg-RX-API-DMAC7.html)
IL205501A (en) Preparation of preparations for the treatment of arthritis
RU2014115290A (ru) Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов
JP2020527173A5 (cg-RX-API-DMAC7.html)
JP2007505931A5 (cg-RX-API-DMAC7.html)
TW200304824A (en) Nicotinamide derivatives useful as PDE4 inhibitors
JP2024510939A5 (cg-RX-API-DMAC7.html)
JP2008517923A5 (cg-RX-API-DMAC7.html)
JP2013542267A5 (cg-RX-API-DMAC7.html)
PT1948176E (pt) Diaril ureias para tratar a hipertensão pulmonar
WO2021170811A1 (en) Method of treating eye disease using trpv4 antagonists
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
HUE027375T2 (en) Phenyl guanidine derivatives